SelectQuote SLQT Q3 2026 Earnings Transcript

SelectQuote reported Q3 revenue of $431 million, up 6% year over year, and adjusted EBITDA of $45 million, up 18%, supported by stronger Senior and Healthcare Services performance. Management reaffirmed full-year guidance of $1.61 billion-$1.71 billion in revenue and $90 million-$100 million in adjusted EBITDA, while noting a $14 million receivables adjustment and cautioning that some of the strong Medicare Advantage approval rates may have been timing-related. The company also highlighted SelectRx efficiency gains, a stable PBM reimbursement environment, and plans to maintain its NYSE listing while evaluating capital markets and M&A options.

Analysis

The market is likely underestimating how much of this quarter was engineered rather than cyclical. The real story is not the headline EBITDA beat, but the combination of higher MA approvals, a larger receivables mark, and a still-healthy book conversion rate that together extend runway for de-levering and, more importantly, for financing optionality. That optionality matters because management is telegraphing several value-unlocking paths at once: receivables monetization, capital markets transactions, and potential consolidation. When a stressed microcap starts talking about liquidity structure and strategic alternatives in the same breath, the next rerating usually comes from balance sheet actions, not operating improvement alone.

The second-order winner is SelectRx economics. The market has focused on reimbursement noise, but the more durable driver is fixed-cost absorption at the Kansas facility, which should keep improving as volume shifts and the new pharmacy system goes live. That creates a compounding effect: lower unit cost improves gross margin, which supports cash generation, which in turn increases the credibility of receivables and makes external financing cheaper. If that sequence holds, the Healthcare Services segment could become the hidden multiple-expansion lever, because investors tend to pay up for visible, self-funding infrastructure-like cash flow.

The key risk is that this quarter may be peak benignity in Senior. Management itself flagged that some approval strength could have been pulled forward, so the next quarter is the cleanest test of whether the business is truly stabilizing or simply benefiting from timing noise. If approvals normalize down, the stock likely retraces because the equity case is heavily dependent on proof that receivables are collectible and recurring cash flow is durable; any slip there hits both valuation and financing perception simultaneously.

Consensus is probably still too anchored to GAAP optics and too dismissive of the asset value embedded in commissions receivable, but the market will not rerate this on narrative alone. The right setup is a trade that benefits from continued operational execution while limiting downside if Q4 proves less impressive. The most likely path to a higher stock price over the next 3-6 months is not a broad healthcare re-rating, but a specific catalyst around capital structure or receivables monetization.

Key Decisions for Investors

• Long SLQT common for 3-6 months: thesis is balance-sheet optionality plus SelectRx margin inflection; target a 30-50% rerating if Q4 confirms approval stability, with downside capped only if receivables skepticism reappears.
• Prefer SLQT call spreads over outright equity for a catalyst window: buy 3-6 month calls / sell higher strike against expected volatility around fourth-quarter approval normalization and any financing headlines.
• Pair trade: long SLQT / short a basket of consumer-facing DTC lead-gen names with weaker cash conversion; SLQT has a clearer path to self-funding, while peers remain dependent on expensive acquisition spend.
• If SLQT rallies >15% before next quarter, trim exposure and wait for Q4 confirmation; the main near-term risk is that current approvals were partly pulled forward, which would compress the next print.
• For more risk-tolerant accounts, use SLQT only as a small tactical long, not a core position, until management either monetizes receivables or proves the 2027 cash-flow bridge with cleaner sequential data.